Target ID & Validation

Target Identification and Validation

Identifying Promising Targets in Early Drug Discovery

  • Easily develop and perform high throughput target ID screens
  • Characterize a wide variety of analytes from small molecule fragments to biologics

Identifying and characterizing promising therapeutic targets is the first step in the drug discovery process. Validating these targets then becomes critical before investing additional time and resources to development. Label-free binding technologies such as Bio-Layer Interferometry (BLI) and Surface Plasmon Resonance (SPR) systems are indispensable tools in both the target identification and validation processes, with high throughput binding screens quickly established.  

The Octet systems are used to identify binding targets and accurately characterize rates of complex formation (ka), complex stability (kd, dissociation) and affinities (KD)


Large Molecules Kinetics Characterization

The Octet family of instruments accurately measures kinetic constants by bringing the detection surface directly to the sample. This fluidics-free approach to label-free, real-time analysis streamlines laboratory workflow, expedites assay development, and allows for direct measurement of crude samples.

Protein - Small Molecules and Peptide Kinetics & Affinity Characterization

In small molecule drug discovery, the path to lead molecules can stem from many sources or starting points including fragment screening, high throughput screening, de novo structural design, etc.  The determination and evaluation of the affinity of small molecule binding to a therapeutic target is a significant component of the drug discovery process. The hit-to-lead and lead optimization process are essential to accurately determine biological potency in vitro so that structure-activity relationships (SAR) can be used for efficient structural design.  Octet BLI and Pioneer SPR platforms are used to characterize small molecule and peptide systems.

Read Application Note

Fragment Screening

Fragment-based drug design has become an increasingly popular platform for the identification of lead candidates in drug discovery programs. The detection and characterization of fragment binding events is facilitated by sensitive biophysical technologies capable of detecting low affinity interactions of low molecular weight compounds. The Pioneer FE has the necessary sensitivity and throughput to provide complete fragment screens on libraries of several thousand compounds in just a few weeks per target.


Cross Competition or Epitope Binning Assays on Octet® RH96 System cover image

Cross Competition or Epitope Binning Assays on the Octet® RH96 System

Epitope binning through cross competition assays is a powerful tool in evaluating functional diversity in antibody clones.

Read Application Note

Customized Quantitation of Recombinant Therapeutic Proteins

Using High Precision Streptavidin Biosensors (SAX)

Read Application Note
A Rapid Method to Quantitatively Screen Bispecific Antibody Using Protein A and His1K Biosensors cover

Screen Bispecific Antibody Using Protein A and His1K Biosensors

Rapid quantitative screening of bispecific antibodies using Protein A and HIS1K biosensors

Read Application Note
Application Note cover

Label-Free Technologies for Accurate Determination of Affinity and...

From target molecule identification to lead selection and optimization, equilibrium affinity and kinetics rate constants are critical parameters...

Read Application Note

Automating Octet Assays for Ligand Screening

Drug development and production is challenging. Avitide, based in Lebanon, New Hampshire, provides on-demand development and supply of...

Read White Paper

Streamlining Affinity Analysis for Accelerated Lead Screening

Antibody and other protein therapeutics are a major focus in drug discovery pipelines today. The overall process for developing protein...

Read White Paper

Kinetic Analysis of Antibody Binding to an Expressed Membrane...

Membrane proteins govern the majority of input and output signals of cells and represent the largest class of pharmaceutical drug targets, making...

Read Application Note

Generating Reliable Kinetic Data for Protein-Ligand Interactions

The Community Structure Activity Resource (CSAR, www.csardock. org) group is developing a database of high quality protein-ligand structures and...

Read Application Note

Commitment to Covalency : Kinetics of Irreversible Inhibitors on...

The principal role of assay groups in drug discovery is to provide reliable methods, analysis, and data for confident decision-making about...

Read Application Note

Fragment Based Drug Discovery on Pioneer Systems Using Next...

Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs.

Read Application Note

OneStep Lead Characterization of High Affinity Biologic...

Biopharmaceutical drug discovery and development have celebrated the approval of breakthrough treatments in diseases of inflammation, cancer and...

Read Application Note

Reducing Variability in Small Molecule Screening and Kinetics...

Minimizing the variability of background signals is a key parameter to the success of demanding applications such as small molecule analysis

Read Application Note

Accelerating Antibody Discovery by Monitoring Titer and...

Significantly reduce time to develop antibodies by combining titer and glycan screening

Download Flyer
Pioneer FE SPR System

Pioneer FE SPR System

Make Decisions Earlier in Fragment Screens with the Pioneer FE

Explore More

Pioneer SPR System

Complete solution for biomolecular interaction analysis with next generation SPR injections

Explore More
Octet HTX

96-Channel Ultra High Throughput Octet System: Octet HTX

Monitors up to 96 biosensors simultaneously, enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed

Explore More
Octet RED384

16-Channel High Throughput Octet System: Octet RED384

The Octet RED384 16-channel instrument provides analytical performance similar to the 8- channel Octet RED96 system, but with higher levels of...

Explore More
Octet RED96e

8-Channel Octet System: Octet RED96e

The 8-channel Octet systems perform quantitation of 96 samples in 32 minutes and kinetic screening of 64 samples in 1.5 hours.

Explore More
Octet QKe

8-Channel Octet System: Octet QKe

Unmatched versatility for discovery, development, and quality control

Explore More
Discover Applications for Titer & Impurity Testing

Related Content


Biologics Characterization Tools

Explore More

Octet System Service and Support

Explore More

Octet System Highlight Resources

Explore More